Victrex plc (LON:VCT) has been assigned a consensus recommendation of “Hold” from the thirteen research firms that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is GBX 2,526.11 ($33.01).
A number of research firms recently weighed in on VCT. Peel Hunt reaffirmed an “add” rating on shares of Victrex in a research note on Wednesday, July 25th. Liberum Capital reaffirmed a “buy” rating and set a GBX 2,825 ($36.91) price target on shares of Victrex in a research note on Wednesday, July 25th. Morgan Stanley upped their price target on Victrex from GBX 1,600 ($20.91) to GBX 2,980 ($38.94) and gave the stock an “equal weight” rating in a research note on Monday, July 16th. Citigroup reaffirmed a “neutral” rating on shares of Victrex in a research note on Tuesday, July 17th. Finally, Barclays reaffirmed an “underweight” rating and set a GBX 2,380 ($31.10) price target (up from GBX 2,300 ($30.05)) on shares of Victrex in a research note on Tuesday, July 24th.
VCT stock traded up GBX 10 ($0.13) during trading on Wednesday, reaching GBX 2,628 ($34.34). 326,282 shares of the stock were exchanged, compared to its average volume of 274,177. Victrex has a twelve month low of GBX 1,826 ($23.86) and a twelve month high of GBX 2,772 ($36.22).
Victrex Company Profile
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. It operates through two segments, Victrex Polymer Solutions and Invibio Biomaterial Solutions. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, dental, trauma, knee, cardiovascular, and orthopedic applications.
Featured Article: Stock Selection – What is cash flow?
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.